OFAKIM, Israel--(BUSINESS WIRE)--NeuroDerm, Ltd., a privately held pharmaceutical company developing transdermal therapies for CNS diseases, announced today that it has raised $2.5 million in a series A round private equity round. The financing round was raised from select private investors including Robert Taub, founder and CEO of Omrix Biopharmaceuticals, Inc. (OMRI: Nasdaq). In conjunction with the financing, Robert Taub and Uwe Wascher, managing director of Wascher & Partner, will join NeuroDerm’s Board of Directors. Previous investors in the company include Ofakim High Tech Ventures and Shmuel Cabilly, PhD.
